In Parkinson's disease, current predominant treatment with intermittent oral administration of levodopa (l-dopa) remains the reference standard, but it has pharmacological drawbacks that trigger motor fluctuations and dyskinesia. To overcome these challenges, we demonstrate greater efficacy in either an ...
Parkinson's disease is a neurodegenerative disease caused by the death of neurons, ie, cells critical to the production of dopamine, an important neurotransmitter in the brain. Here, we present a brief review of the dopamine synthetic pathway, binding to the dopamine receptors, and subsequent acti...
Parkinson's disease is a movement disorder characterized by degeneration of dopamine-producing neurons. At early stages, pharmacological replacement treatment with dopamine receptor agonists or the dopamine precursor, L-DOPA, can cause symptomatic relief. However, ultimately these treatments are insufficient...
Morelli M, Pinna A (2002) Interaction between dopamine and adenosine A 2A receptors as a basis for the treatment of Parkinson’s disease. Neurol Sci ... M Morelli,A Pinna - 《Neurological Sciences Official Journal of the Italian Neurological Society & of the Italian Society of Clinical Neuroph...
In treating Parkinson's disease with dopaminergic agonists, such as pramipexole, ropinirole, pergolide, rotigotine, apomorphine, or bromocriptine, it has been observed that a significant number of patients develop impulse–control disorders, such as compulsive shopping, pathological gambling, or hypersexual...
PURPOSETo evaluate the safety and efficacy of risperidone in patients with Parkinson's disease (PD) who are experiencing significant dopamine-induced psychosis.PATIENTS AND METHODSSeventeen patients (median age, 72 yrs) participated in this 12-week, open pilot study receiving 0.5 to 3 mg oral rispe...
Dopamine agonists are established as effective drugs for the symptomatic treatment of Parkinson鈥檚 disease (PD) throughout its course. As monotherapy, they produce effective control of motor symptoms and combine this with a low risk for motor complications. As an adjunct to levodopa, they improve...
"therapeutic interventions that restore normal synchronicity in these circuits, using either pharmacological or electrophysiological manipulations, and targeted not only to basal ganglia but also directly to motor cortex can be potentially beneficial to DA-related motor dysfunction and Parkinson's disease."...
Levodopa is the gold-standard therapy for Parkinson's disease. However, long-term treatment leads to involuntary movements and response fluctuations which add to the complexities of later disease-management. In addition, preclinical evidence suggests that levodopa is toxic to dopaminergic neurons. These...
The medical treatment of Parkinson disease from James Parkinson to George Cotzias Carlsson then developed a highly sensitive assay to measure dopamine, and his lab found that dopamine is selectively present in high concentrations in the ... S Fahn - 《Mov Disord》 被引量: 50发表: 2015年 What...